The aims of the Neuropathology Core are: To establish a comprehensive and standardized histopathological service to research groups in the Program. ? To provide advice and expertise on neuropathological interpretation to research groups in the Program. ? To record histopathological findings and assessments in a form that is both accessible to the research groups in the Program and readily integrated with other data for the purposes of comparative analysis. ? To establish a comparative classification of human and mouse model CNS tumors. A uniform approach to histological analysis is essential to this Program. High quality methodologies and expert evaluation of preparations will enable a robust and detailed characterization of human and mouse central nervous system (CNS) tumors from across the Program. There is scope for a detailed comparative analysis at histological and molecular levels of human and mouse model CNS tumors, both within one histopathological category, e.g. primitive neuroectodermal tumors (PNETs), and across categories, e.g. PNETs versus gliomas. Histopathological analysis will be critical for validation of genetic modification in mouse model tumors, human and mouse tumor cell characterization at the immunohistochemical and molecular cytogenetic levels, and determining the effects of novel small-molecule pharmacological agents. New diagnostic approaches combining histopathological and molecular analyses will be generated by these studies, and could form the basis for patient stratification in future clinical trials of novel therapies

Public Health Relevance

An increased understanding of the development and biology of brain tumors in childhood will advance treatment of these devastating diseases. Central to such therapeutic advances will be novel diagnostic approaches that combine histopathological and molecular analyses, so that treatment can be tailored to specific characteristics in tumor cells. As part of this Program, the Neuropathology Core expects to develop such novel diagnostic approaches for a range of childhood brain tumors

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-GRB-S)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
St. Jude Children's Research Hospital
United States
Zip Code
Zhan, Hong; Aizawa, Kenichi; Sun, Junqing et al. (2016) Ataxia telangiectasia mutated in cardiac fibroblasts regulates doxorubicin-induced cardiotoxicity. Cardiovasc Res 110:85-95
Grigaravicius, P; Kaminska, E; Hübner, C A et al. (2016) Rint1 inactivation triggers genomic instability, ER stress and autophagy inhibition in the brain. Cell Death Differ 23:454-68
Qaddoumi, Ibrahim; Orisme, Wilda; Wen, Ji et al. (2016) Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol 131:833-45
Sturm, Dominik; Orr, Brent A; Toprak, Umut H et al. (2016) New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell 164:1060-72
Baker, Suzanne J; Ellison, David W; Gutmann, David H (2016) Pediatric gliomas as neurodevelopmental disorders. Glia 64:879-95
Phoenix, Timothy N; Patmore, Deanna M; Boop, Scott et al. (2016) Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell 29:508-22
Zhai, Yali; Kuick, Rork; Tipton, Courtney et al. (2016) Arid1a inactivation in an Apc- and Pten-defective mouse ovarian cancer model enhances epithelial differentiation and prolongs survival. J Pathol 238:21-30
Zhu, Liqin; Finkelstein, David; Gao, Culian et al. (2016) Multi-organ Mapping of Cancer Risk. Cell 166:1132-1146.e7
Patel, Yogesh T; Jacus, Megan O; Davis, Abigail D et al. (2016) Simvastatin Hydroxy Acid Fails to Attain Sufficient Central Nervous System Tumor Exposure to Achieve a Cytotoxic Effect: Results of a Preclinical Cerebral Microdialysis Study. Drug Metab Dispos 44:591-4
Morfouace, Marie; Nimmervoll, Birgit; Boulos, Nidal et al. (2016) Preclinical studies of 5-fluoro-2'-deoxycytidine and tetrahydrouridine in pediatric brain tumors. J Neurooncol 126:225-34

Showing the most recent 10 out of 168 publications